Marilyn Kwan to Aromatase Inhibitors
This is a "connection" page, showing publications Marilyn Kwan has written about Aromatase Inhibitors.
Connection Strength
2.679
-
Endocrine therapy adherence and 10-year cardiometabolic risk in hormone receptor-positive breast cancer. JNCI Cancer Spectr. 2026 Nov 02; 10(6).
Score: 0.965
-
Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy. Breast Cancer Res Treat. 2018 Apr; 168(2):523-530.
Score: 0.522
-
Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer. Cancer Causes Control. 2017 Jun; 28(6):557-562.
Score: 0.496
-
Bone health history in breast cancer patients on aromatase inhibitors. PLoS One. 2014; 9(10):e111477.
Score: 0.420
-
Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study. Breast Cancer Res Treat. 2020 Feb; 180(1):187-195.
Score: 0.150
-
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011 Apr; 126(2):529-37.
Score: 0.079
-
Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer. Breast Cancer Res Treat. 2023 Aug; 201(1):117-126.
Score: 0.048